As Congress focuses on how to drive down drug prices, there is bipartisan support for prohibiting reverse payment agreements, also known as “pay-for-delay” arrangements. These arrangements involve a brand-name pharmaceutical manufacturer paying one or more potential generic competitors to delay bringing a generic to market as part of a resolution to a patent infringement lawsuit.
Senate Judiciary Committee: “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition”
Tuesday, May 7, 2019: The Senate Judiciary Committee held a hearing on practices by drug manufacturers to delay the patent system and extend monopolies on prescription drugs. Find witness testimonies, live feed and other information here.
Why this is …
This week in Washington: Hearings continue on the price of prescription drugs, Senate Committee on Finance to hold a hearing on Medicare physician payment reform, while the Senate HELP Committee will hold its second hearing in a series on electronic health information and further implementing the 21st Century Cures Act.
House Committee on Rules: …
Tuesday, April 30, 2019
House Committee on Rules: “Hearing on the Medicare for All Act of 2019,” H.R. 1384
The House Committee on Rules will hold a hearing on the Medicare for All Act of 2019. This hearing will be the first time Congress has ever held a hearing on Medicare for…
House Judiciary Committee: “TBA Markup on CREATES Act, Pay-for-Delay Legislation”
The House Judiciary Committee is planning a markup on the CREATES Act and pay-for-delay legislation. The date of the markup is to be announced. Last month, Judiciary Committee Chair Jerrold Nadler (D-NY) said he intended to introduce a bill to prohibit deals in which…
Senate Finance Committee: “Drug Pricing in America: A Prescription for Change, Part III”
Tuesday, April 9, 2019: The Senate Finance Committee continued its drug pricing series by inviting pharmacy benefit manager companies (PBMs) to testify before the committee. The invitation was extended on March 12 to Cigna, CVS Caremark and CVS Health, Humana, OptumRx…
House Committee on Energy and Commerce: “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Costs”
Tuesday, April 2, 2019: The Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce will hold a hearing to address the consequences of rising insulin costs. This was the second hearing on…
House Committee on the Budget: “Department of Health and Human Services FY2020 Budget”
Tuesday, March 26, 2019: The House Committee on the Budget held a hearing examining the proposed FY2020 budget for the Department of Health and Human Services (HHS) with Deputy Secretary of HHS Eric Hargan. Find a link to witness testimonies, member…
Oversight Committee Seeks Purdue OxyContin Documents
On March 21, House Oversight Committee Chairman Elijah Cummings (D-MD) and Rep. Mark DeSaulnier (D-CA) sent a letter to Purdue Pharma requesting documents related to how it has aggressively marketed OxyContin, a key player in the ongoing opioid crisis. The documents requested include the list of Sacklers, the…
House Committee on Energy and Commerce: “The Fiscal Year 2020 HHS Budget”
Tuesday, March 12, 2019: The Health Subcommittee held a hearing with Health and Human Services Secretary (HHS) Alex Azar on President Trump’s budget request related to the U.S. Department of Health and Human Services (HHS) and its agencies for fiscal year (FY)…